Ritu Baral
Stock Analyst at TD Cowen
(0.60)
# 3,765
Out of 4,711 analysts
37
Total ratings
27.59%
Success rate
-24.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $5.61 | +60.43% | 6 | Nov 21, 2024 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $0.96 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.26 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $31.82 | +145.13% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $245.44 | +51.16% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $70.44 | +39.13% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $308.44 | +26.44% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $4.95 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $118.97 | +47.10% | 1 | Mar 22, 2023 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $32 → $21 | $16.87 | +24.48% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.40 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.95 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.85 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.19 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $42.60 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.86 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.21 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.03 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $631.69 | - | 2 | Jan 12, 2018 |
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $5.61
Upside: +60.43%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.96
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.26
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $31.82
Upside: +145.13%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $245.44
Upside: +51.16%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $70.44
Upside: +39.13%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $308.44
Upside: +26.44%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.95
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $118.97
Upside: +47.10%
ACADIA Pharmaceuticals
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $16.87
Upside: +24.48%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.40
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.95
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.85
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.19
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $42.60
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.86
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $13.21
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.03
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $631.69
Upside: -